

# Robert Battat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5947284/publications.pdf>

Version: 2024-02-01

56  
papers

1,801  
citations

279487

23  
h-index

288905

40  
g-index

57  
all docs

57  
docs citations

57  
times ranked

2375  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e361-e379.	2.4	68
2	Advances in the Comprehensive Management of Postoperative Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1436-1449.	2.4	19
3	Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 224-243.	0.6	9
4	Fucosyltransferase 2 Mutations Are Associated With a Favorable Clinical Course in Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e166-e170.	1.1	1
5	Machine learning models and over-fitting considerations. <i>World Journal of Gastroenterology</i> , 2022, 28, 605-607.	1.4	34
6	Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1865-1871.	0.9	3
7	Authors' Reply to "Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease". <i>Inflammatory Bowel Diseases</i> , 2022, 28, e61-e61.	0.9	0
8	Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3563-3569.	1.1	3
9	Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1443-1451.	0.9	18
10	Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 511-518.e6.	2.4	28
11	A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, e176-e182.	1.1	4
12	Therapeutic Drug Monitoring of Certolizumab Pegol: Can Real-World Data Translate to Clinical Practice?. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	0.5	0
13	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <i>Gastroenterology</i> , 2021, 160, 2291-2302.	0.6	57
14	No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2312-2314.e3.	2.4	12
15	Serum Ustekinumab Concentrations Are Associated With Remission in Crohn's Disease Defined by a Serum-Based Endoscopic Healing Index. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	0.5	3
16	Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data. <i>American Journal of Gastroenterology</i> , 2021, 116, 2029-2031.	0.2	1
17	Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000774.	1.1	20
18	Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 801532.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Endoscopist-Directed Propofol as an Adjunct to Standard Sedation: A Canadian Experience. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 141-144.	0.1	4
20	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10.	0.6	65
21	Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 15-32.	0.3	3
22	Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097121.	1.4	7
23	Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 568-569.	1.9	0
24	Defining the phenotype, pathogenesis and treatment of Crohn's disease-associated spondyloarthritis. <i>Journal of Gastroenterology</i> , 2020, 55, 667-678.	2.3	9
25	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 885-894.	0.2	15
26	Editorial: calcineurin inhibitors as a bridge to vedolizumab for severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 663-664.	1.9	2
27	Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1031-1038.	1.9	80
28	S0783 Markedly Elevated 7- $\beta$ -hydroxy-4-cholesten-3-one (C4) Is Associated With Fat Malabsorption in the Setting of Short Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2020, 115, S400-S400.	0.2	1
29	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1574-1582.	1.9	5
30	Innovations in Oral Therapies for Inflammatory Bowel Disease. <i>Drugs</i> , 2019, 79, 1321-1335.	4.9	51
31	Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 848-857.	1.9	40
32	Tu1835 Association Between Vedolizumab Trough Concentration and Clinical Outcomes in Patients with Inflammatory Bowel Diseases: Implications for Clinical Practice. <i>Gastroenterology</i> , 2019, 156, S-1143.	0.6	1
33	Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 127-145.	0.3	30
34	A product review of vedolizumab in inflammatory bowel disease. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2482-2490.	1.4	20
35	Serum Concentrations of 7- $\beta$ -hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2722-2730.e4.	2.4	26
36	Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. <i>Drug Safety</i> , 2019, 42, 617-632.	1.4	17

#	ARTICLE	IF	CITATIONS
37	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101602.	1.0	19
38	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 733-745.	0.2	42
39	Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 319-330.	1.4	37
40	Reply to Letter on: "Risk Factors Associated With <i>Clostridium difficile</i> Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis". <i>Journal of Crohn's and Colitis</i> , 2019, 13, 536-537.	0.6	0
41	Risk Factors Associated with <i>Clostridium difficile</i> Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 27-38.	0.6	49
42	Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 410-420.	0.9	28
43	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 129-146.	0.3	64
44	Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn's disease: Systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2017, 49, 854-863.	0.4	101
45	Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1427-1434.e2.	2.4	187
46	Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1361-1367.	0.8	12
47	Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2982-2990.	1.1	36
48	Management of inflammatory bowel disease with <i>Clostridium difficile</i> infection. <i>World Journal of Gastroenterology</i> , 2017, 23, 4986.	1.4	62
49	Practice guidelines for endoscopic ultrasound-guided celiac plexus neurolysis. <i>Endoscopic Ultrasound</i> , 2017, 6, 369.	0.6	37
50	Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. <i>World Journal of Gastroenterology</i> , 2016, 22, 7727.	1.4	65
51	The Haiti Medical Education Project: development and analysis of a competency based continuing medical education course in Haiti through distance learning. <i>BMC Medical Education</i> , 2016, 16, 275.	1.0	16
52	Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1137-1144.	0.8	87
53	Hematologic Indices as Surrogate Markers for Monitoring Thiopurine Therapy in IBD. <i>Digestive Diseases and Sciences</i> , 2015, 60, 478-484.	1.1	23
54	Vitamin B12 Deficiency in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1.	0.9	78

#	ARTICLE	IF	CITATIONS
55	Global health competencies and approaches in medical education: a literature review. BMC Medical Education, 2010, 10, 94.	1.0	191
56	Serum Monitoring of Recurrence in Post-Operative Crohn's Disease: Have We Arrived?. Journal of Crohn's and Colitis, 0, , .	0.6	3